MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register
About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Industry news

Related news

Latest News

AMT Successful in Preclinical Treatment of DMD
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
Enobia Pharma Expands Clinical Program for ENB-0040, a Bone-Targeted Enzyme Replacement Therapy for Hypophosphatasia
GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus
AXIS-SHIELD RECEIVES FDA CLEARANCE FOR THE ANTI-CCP RHEUMATOID ARTHRITIS TEST ON ABBOTT'S ARCHITECT ANALYSER
Lpath's iSONEP Is Well Tolerated at All Dose Levels in a Phase 1 Trial in Wet-AMD Patients
More news... | RSS Feed...

Most Viewed

GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus

Enobia Pharma Expands Clinical Program for ENB-0040, a Bone-Targeted Enzyme Replacement Therapy for Hypophosphatasia

AXIS-SHIELD RECEIVES FDA CLEARANCE FOR THE ANTI-CCP RHEUMATOID ARTHRITIS TEST ON ABBOTT'S ARCHITECT ANALYSER

Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic

Lpath's iSONEP Is Well Tolerated at All Dose Levels in a Phase 1 Trial in Wet-AMD Patients

AMT Successful in Preclinical Treatment of DMD

Therapeutic Target

Cardiovascular
Dermatology
Endocrine and Metabolic
Gastroenterology
Genitourinary
Hematology
Immunology and Allergy
Infection
Musculoskeletal
Neurology
Obstetrics and Gynecology
Oncology
Ophthalmology
Psychiatry
Pulmonary

Categories

Deals and Alliances
Development
Financial Results
Financings
Intellectual Property
Regulatory
Press releases
Deals review
Headlines
PR Newswire

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us